Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD)

Phase 4UnknownNCT00862108

Seoul National University Hospital50 enrolled

Overview

The purpose of this study is to determine whether norepinephrine gene polymorphism affect to treatment response in ADHD

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

MethylphenidateDRUG

mg/kg dose: 0.7\~1.2mg/kg PO daily morning intake 8 weeks

Eligibility

Sex: ALLMin age: 6 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosis made by DSM-IV and K-SADS-PL * IQ \> 71 Exclusion Criteria: * genetic disorder * history of acquired brain injury * seizure disorder * other neurologic disorder * mental disorder, pervasive developmental disorder * obsessive-Compulsive disorder * communication disorder * learning disorder

Locations (1)

Seoul National University Hospital

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Clinical Global Impression Scale-Improvement

Time frame: 8 weeks

Secondary Outcomes

ADHD rating scale

Time frame: 8 weeks

Central Contacts

Soo-Churl Cho, MD, PhD

CONTACT

82-2-2072-3648 jewook.kang@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.